About us

Venatorx Pharmaceuticals is a private company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. The company name, Venatorx (ven-a-TOREX), derives from the Latin word “venator”, meaning ‘hunter’ and “rx”, the medical symbol for drugs. The pursuit, or “hunt”, for new drugs is the core mission of our company. Founded in 2010, Venatorx has built a world-class in-house research and development organization that has filed over 120 patents. Venatorx’s two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam / beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively. In addition, the first Venatorx antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor, is in Phase 1 clinical development. The Company also has discovery-stage programs targeting a novel class of non-beta-lactam antibiotics called Penicillin Binding Protein (PBP) inhibitors that have the potential to circumvent 70+ years of resistance and usher in a new wave of antibacterial therapeutics.

 

Awards

 
2021
 
2019
 
2019
(L to R) Drs. Daniel C. Pevear, Christopher J. Burns, Luigi Xerri
 
2019
Dr. Christopher J. Burns

 

History

Venatorx Pharmaceuticals was founded in June 2010 by our three visionary, fearless leaders Drs. Christopher J. Burns, Daniel C. Pevear and Luigi Xerri. Fast forward to today, we have 80+ employees, three programs discovered in-house that are now clinical stage, with more in the pipeline!! Cheers to the many milestones to come as we work purposefully every day to get antibiotics and antiviral therapies into the hands of physicians to effectively treat patients. Below just a few of the highlights!

2010
Venatorx founded by Drs. Burns, Pevear and Xerri
2013
Venatorx Completes $3.5M Series A Financing
2017
Venatorx Raises $42M Series B Financing
2018
Venatorx Named Best Places to Work
2019
Venatorx Founders named EY ‘Entrepreneurs of the Year’
2020
Venatorx Partners with GARDP
2021
Venatorx Expands Anti-Infective Portfolio with HBV Candidate